Laureano Mestra

Laureano Mestra

Auto-generated profile, based on publicly available information

Laureano Mestra

Control and Research in Tropical Diseases Program – PECET, Universidad de Antioquia, Medellín, Colombia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2010 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
IVIván Vélez
Iván Vélez
LLLiliana López
Liliana López
XSXimena Sánchez
Ximena Sánchez
LMLaureano Mestra
Laureano Mestra
CRCarlos Rojas
Carlos Rojas
ERErwin Rodríguez
Erwin Rodríguez
Miltefosine is an oral agent used for cutaneous leishmaniasis treatment. An open-label, randomized, phase III clinical trial was carried out in the Colombian army population. Miltefosine, 50 mg capsule was taken orally three times per day for 28 days (N = 145) or meglumine antimoniate, 20 mg/kg body weight per day for 20 days by intramuscular injection (N = 143). The efficacy of miltefosine by protocol was 69.8% (85/122 patients) and 58.6% (85/145 patients) by intention to treat. For meglumine antimoniate, the efficacy by protocol was 85.1% (103/121 patients) and 72% (103/143 patients) by intention to treat. No association was found between drug efficacy and L. (V.) braziliensis or L. (V.) panamensis species of Leishmania responsible for infection. Adverse gastrointestinal events were associated with the use of miltefosine, the meglumine antimoniate treatment was associated with adverse effects on the skeletal musculature, fever, cephalea, and higher toxicity in kidney, liver, pancreas, and hematological system.

22 July 2011 in Lupus
Verified
Journal Article
Closed access
LPLf Pinto
Lf Pinto
CVCj Velásquez
Cj Velásquez
CPC Prieto
C Prieto
LML Mestra
L Mestra
EFE Forero
E Forero
JMJd Márquez
Jd Márquez
Despite aggressive treatment for systemic lupus erythematosus (SLE) with high-dose glucocorticoids and immunosuppressive agents, a significant proportion of patients persist with activity or relapse. Although the results from randomized studies showed no beneficial effects of rituximab (RTX) in SLE, this treatment has proven promising results in open label trials including patients with severe and refractory disease. We report a prospective cohort of 42Colombian patients with severe and refractory SLE treated with RTX after failure response to glucocorticoids and, at least, another immunosuppressive drug. We observed a reduction in steroid requirement [47.4 mg/day at 24 months (p < 0.001)]. Since the first three-month follow-up, 28% and 36% of the patients fulfilled criteria of complete or partial remission according to proteinuria, and 12.5% and 33% according to creatinine clearance, respectively. These response criteria remained at 12 months. Both neuropsychiatric and hematological sub-groups had a favorable clinical response. The median reinfusion-free survival time was 44months (95% confidence interval: 10.1–50.1) and 80% of the patients did not require RTX reinfusion. Eleven adverse events were reported in 28 subjects. Most of these occurred during the first three-month follow-up, time during which patients were exposed to high-dose glucocorticoids.

10 March 2011 in Transfusion
Verified
Journal Article
Closed access
PDF file
LMLaureano Mestra
Laureano Mestra
LLLiliana Lopez
Liliana Lopez
SRSara M. Robledo
Sara M. Robledo
CMCarlos Muskus
Carlos Muskus
RNRubén S. Nicholls
Rubén S. Nicholls
IVIván Darío Vélez
Iván Darío Vélez